BioNTech co-founders set to launch new mRNA venture as company sharpens oncology focus

BioNTech SE (NASDAQ:BNTX) co-founders Ugur Sahin and Özlem Türeci plan to launch a new independent biotech company focused on next-generation mRNA technologies, the German vaccine developer said on Tuesday, as it intensifies its focus on oncology. BioNTech said it will contribute certain related rights and technologies to the new venture in exchange for a minority stake, with potential milestone payments and royalties.